A Multicentre, Double-Blind, Parallel, Randomized, Placebo-Controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR).
Phase of Trial: Phase IV
Latest Information Update: 30 Oct 2014
At a glance
- Drugs Levocetirizine (Primary) ; Desloratadine
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Acronyms LEADER
- Sponsors UCB Pharma Inc
- 10 Jul 2007 Status changed from in progress to completed.
- 07 Nov 2005 New trial record.